Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?

Journal of Clinical Oncology

Volumn 27, Issue 13, 2009, Pages 2293-2294

  Dasanu, Constantin A ^a   Alexandrescu, Doru T ^b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b Georgetown Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STEROID; VINCA ALKALOID; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CD45 ANTIGEN; PYRAZINE DERIVATIVE;

CANCER CHEMOTHERAPY; DRUG SURVEILLANCE PROGRAM; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MULTIPLE MYELOMA; NATURAL KILLER CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VIRUS REPLICATION; DRUG EFFECT; IMMUNOLOGY; NOTE; PHYSIOLOGY; VIRUS ACTIVATION;

ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HERPESVIRUS 3, HUMAN; HUMANS; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; PYRAZINES; VIRUS ACTIVATION;

EID: 65549137560     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.0138     Document Type: Letter

References (12)

1. Chanan-Khan A, Sonneveld P, Schuster MW, et al: Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784-4790, 2008
2. Morison WL: Letter: Herpes simplex and herpes zoster in neoplasia. Lancet 1:1293, 1974
3. Schütt P, Brandhorst D, Stellberg W, et al: Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 47:1570-1582, 2006 (Pubitemid 44364023)
4. Rajkumar SV, Richardson PG, Hideshima T, et al: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639, 2005 (Pubitemid 46224241)
5. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107:3575-3583, 2006
6. Maseda D, Meister S, Neubert K, et al: Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 15:600-612, 2008 (Pubitemid 351267310)
7. Jewett A, Head C, Cacalano NA: Emerging mechanisms of immunosuppression in oral cancers. J Dent Res 85:1061-1073, 2006 (Pubitemid 44935523)
8. Subklewe M, Sebelin-Wulf K, Beier C, et al: Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 68:147-155, 2007 (Pubitemid 46356651)
9. Neznanov N, Dragunsky EM, Chumakov KM, et al: Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS ONE 3:e1887, 2008 (Pubitemid 351954398)
10. Niesvizky R, Richardson PG, Rajkumar SV, et al: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143:46-53, 2008
11. Izzedine H, Launay-Vacher V, Deray G: Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45:804-817, 2005
12. Schreiber R, Wolpin J, Koren G: Determinants of aciclovir-induced nephrotoxicity in children. Paediatr Drugs 10:135-139, 2008